arrow
M

Merit Cudkowicz

Harvard University
H指数:92
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, tolerability, and efficacy of RIPK1 inhibitor, SAR443820, in amyotrophic lateral sclerosis (HIMALAYA): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

RIPK1抑制剂SAR443820在肌萎缩侧索硬化症中的安全性、耐受性和有效性(HIMALAYA):一项多中心、随机、双盲、安慰剂对照的2期临床试验

2026-09-090
PRE
Author Correction: Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis

作者更正: 肌萎缩性侧索硬化症对C9orf72蛋白的自身免疫反应

Nature
IF48.5
2026-03-180
OAAI
Autoimmune response to C9orf72 protein in amyotrophic lateral sclerosis

肌萎缩侧索硬化症中针对C9orf72蛋白的自身免疫反应

Nature
IF48.5
2025-10-010
OA
ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease

ENLITE PD:一项针对帕金森病患者睡眠障碍的光疗随机临床试验

2025-09-060
PRE
Hospitalizations as an outcome measure in COURAGE-ALS

COURAGE-ALS研究中以住院治疗作为结局指标

2025-06-120
OA
Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial

利德尔西米夫在肌萎缩侧索硬化症中的应用:COURAGE-ALS随机临床试验的结果

2025-05-010
PRE
Allogeneic B cell immunomodulatory therapy in amyotrophic lateral sclerosis
2024-07-050
PRE
The extinguish trial: A phase-2B randomized placebo-controlled trial of inebilizumab in anti-NMDA receptor encephalitis
2023-12-010
PRE
Effects of AFQ056 on language learning in fragile X syndrome
2023-08-313
OAAI